The content on this site is intended for healthcare professionals only
PARP inhibitors and prostate cancer: A new era of precision medicine
Oncology pharmacist perspective on PARP inhibitors for castration-resistant prostate cancer
The role of PARP-2 in inhibiting prostate cancer
Lung cancer updates from ASCO 2020
KEYNOTE-427 updates: First-line pembrolizumab monotherapy in patients with advanced clear cell renal cell carcinoma
Association of gene expression with clinical outcomes in RCC patients treated with pembrolizumab
Renal cell cancer: Highlights from ASCO 2020
FRACTION-RCC: Evaluating nivolumab plus ipilimumab in patients with treatment-refractory advanced renal cell carcinoma
HERO: Relugolix versus leuprolide acetate for advanced prostate cancer
The future of PARP inhibitors in prostate cancer
COMBI-AD trial: Adjuvant dabrafenib plus trametinib in patients with resected stage III BRAF V600–mutant melanoma
IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial cancer
Checkmate 9LA: Nivolumab, ipilimumab and chemotherapy for stage IV NSCLC
MINDACT long-term results: 70-gene signature MammaPrint to guide adjuvant chemotherapy use in breast cancer
Early safety from a trial of talimogene laherparepvec (T-VEC) injected into liver tumours plus pembrolizumab
CITYSCAPE: Tiragolumab plus atezolizumab for non-small cell lung cancer
Phase II data from the KarMMa trial for relapsed/refractory multiple myeloma
Pembrolizumab vs brentuximab vedotin in relapsed or refractory classic Hodgkin lymphoma
Perioperative chemotherapy with mFOLFIRINOX vs gemcitabine/nab-paclitaxel for resectable pancreatic ductal adenocarcinoma
High-dose twice daily thoracic radiotherapy in limited disease small-cell lung cancer
ASPEN: Results of a phase III randomised trial of zanubrutinib vs ibrutinib for patients with Waldenström macroglobulinemia
Background of the KEYLYNK-007 trial for advanced solid tumours
Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer
CTC count as a prognostic marker for androgen deprivation plus orteronel or bicalutamide in mCSPC
AGO DESKTOP III/ENGOT-ov20: Impact of secondary cytoreductive surgery in recurrent ovarian cancer
Three versus six months of adjuvant oxaliplatin and fluoropyrimidine-based therapy for patients with stage III colon cancer
Checkpoint inhibitors for the treatment of advanced hepatocellular carcinoma
Reducing damage to swallowing muscles during radiotherapy for head and neck cancers
Comment: JAVELIN-100 for metastatic urothelial cancer
HCRN GU16-260: Nivolumab and salvage nivolumab ipilimumab in treatment-naïve patients with advanced renal cell carcinoma
Updated results from KEYNOTE-426 for metastatic kidney cancer
3-weekly cisplatin or weekly cisplatin for squamous cell carcinoma of head and neck
Osimertinib plus gefitinib for treatment of EGFR-mutated non-small cell lung cancer
METex14 SAs (MET exon 14 skipping alterations) in non-small cell lung cancer
PARP inhibitors in prostate cancer: Choices of tests and how to test?
ASCO 2020: Breast cancer roundup
FORTE trial: Minimal residual disease evaluation in newly diagnosed multiple myeloma
The PANDA study: Combining panitumumab with FOLFOX or 5FU in elderly patients with RAS-BRAF WT metastatic colorectal cancer
Comparing pevonedistat plus azacitidine versus azacitidine alone in patients with higher-risk MDS/CMML or low-blast AML
Perioperative novel systemic immunotherapy-based approaches in urinary cancers
ASCO 2020: Updates in renal cancer
TROPHIMMUN: Avelumab for gestational trophoblastic tumours resistant to monochemotherapy
KEYNOTE-177 results: Pembrolizumab versus chemotherapy for patients with MSI-H/dMMR colorectal cancer
Highlights from ASCO 2020
PARP inhibitors in prostate cancer: Guidelines, who to test and the patient pathway
Timing of response to venetoclax combination treatment in older patients with acute myeloid leukaemia
CheckMate 227 three-year update: Nivolumab plus ipilimumab versus chemo as first-line treatment for advanced NSCLC
ASCO 2020: Latest developments in EGFR-mutated non-small cell lung cancer
Venetoclax with bortezomib and dexamethasone in relapsed/refractory multiple myeloma
KRd vs VRd for initial therapy of newly diagnosed multiple myeloma
Teclistamab for patients with heavily pretreated relapsed or refractory multiple myeloma
E2108: Systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer
KEYNOTE-604: Pembrolizumab plus etoposide and platinum as a first-line therapy for extensive-stage small-cell lung cancer
Clinical impact of COVID-19 on patients with cancer: Data from the COVID-19 and Cancer Consortium (CCC19)
Cumulative incidence of financial hardship in metastatic colorectal cancer patients: Primary endpoint results for SWOG S1417CD
Denosumab in multiple myeloma patients with renal insufficiency
Association of BRCA alterations with response to PARP inhibitors in metastatic castration-resistant prostate cancer
LuPSMA vs cabazitaxel in metastatic castration-resistant prostate cancer progressing after docetaxel
The paediatric precision oncology study INFORM: Clinical outcome and benefit for molecular subgroups
Maintenance avelumab plus best supportive care (BSC) versus BSC alone after chemotherapy in advanced urothelial carcinoma
Better genetic diagnostics in Ugandan breast cancer patients
Cisplatin plus/minus veliparib in metastatic TNBC and/or germline BRCA-associated breast cancer
Update from KAITLIN for high-risk HER2-positive early breast cancer
CARTITUDE-1: JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy for r/r multiple myeloma
Sym015 shows superior specificity compared to TKIs for NSCLC
Brigatinib for NSCLC, latest research and overcoming complications
ADAURA results: Adjuvant osimertinib for EGFRm non-small cell lung cancer
Pembrolizumab plus chemotherapy for patients with metastatic triple-negative breast cancer
